Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
AILERON THERAPEUTICS INC (ALRN)
Sector: Healthcare; Industry: Biotechnology

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-01-08 Satter Muneer A Director Buy 9,000,000 $1.10 $9,900,000 No
2020-06-15 Ambros Reinhard J. Director Buy 5,800 $1.22 $7,076 No
2020-06-08 VON RICKENBACH JOSEF H Director Buy 227,272 $1.10 $249,999 No
2020-06-08 Satter Muneer A 10%-Owner, Director Buy 3,700,000 $1.10 $4,070,000 No
2019-11-15 Bailey Jeffrey Allen Director Buy 55,000 $0.51 $28,050 No
2019-11-12 Bailey Jeffrey Allen Director Buy 19,894 $0.53 $10,544 No
2019-09-13 VON RICKENBACH JOSEF H Director Buy 113,145 $0.98 $110,505 No
2019-09-04 VON RICKENBACH JOSEF H Director Buy 23,225 $0.71 $16,583 No
2019-09-03 VON RICKENBACH JOSEF H Director Buy 28,466 $0.72 $20,396 No
2019-08-29 VON RICKENBACH JOSEF H Director Buy 3,600 $0.77 $2,771 No
2019-08-16 Vukovic Vojo SVP, Chief Medical Officer Buy 75,000 $0.59 $44,452 No
2019-08-13 Gregory Kathryn SVP, Chief Business Officer Buy 45,000 $0.65 $29,025 No
2019-04-01 Novartis Bioventures Ltd 10%-Owner Sell 127,150 $1.86 $236,258 No
2019-03-15 Novartis Bioventures Ltd 10%-Owner Sell 190,338 $2.06 $391,445 No
2018-08-20 Novartis Bioventures Ltd 10%-Owner Sell 20,388 $2.30 $46,892 No
2018-08-17 Novartis Bioventures Ltd 10%-Owner Sell 17,508 $2.10 $36,767 No
2018-08-15 Novartis Bioventures Ltd 10%-Owner Sell 5,935 $2.21 $13,123 No
2018-08-10 LONGENECKER JOHN P PHD President and CEO Buy 10,000 $2.45 $24,500 No
2018-08-13 Novartis Bioventures Ltd 10%-Owner Sell 7,215 $2.42 $17,477 No
2017-07-05 Kapnick Scott 10%-Owner, Director Buy 66,666 $15.00 $999,990 No
2018-08-09 Novartis Bioventures Ltd 10%-Owner Sell 1,235 $2.72 $3,363 No
2018-08-07 Novartis Bioventures Ltd 10%-Owner Sell 4,681 $3.00 $14,050 No
2018-08-02 Novartis Bioventures Ltd 10%-Owner Sell 4,702 $3.33 $15,658 No
2018-08-01 Novartis Bioventures Ltd 10%-Owner Sell 12,681 $3.17 $40,158 No
2018-07-30 Novartis Bioventures Ltd 10%-Owner Sell 8,458 $3.35 $28,368 No
2018-07-26 Novartis Bioventures Ltd 10%-Owner Sell 20,397 $3.76 $76,658 No
2018-07-24 Novartis Bioventures Ltd 10%-Owner Sell 31,300 $4.25 $132,927 No
2018-07-17 Novartis Bioventures Ltd 10%-Owner Sell 12,800 $4.72 $60,420 No
2018-06-26 APPLE TREE PARTNERS II LP 10%-Owner Sell 106,257 $5.92 $629,522 No
2018-06-21 APPLE TREE PARTNERS II LP 10%-Owner Sell 6,647 $5.30 $35,233 No

Insider Smart

Mohawk Group Holdings, Inc. (MWK) - Multiple insiders bought MWK in June around $5, stock moved sideways for a month then made a 60% jump in 10 days. Patience is the key.

Insider Smart

SIMON PROPERTY GROUP (SPG) - Bottom fishing the crash could be intimidating, but it can be easier if you know insiders are on your side. Aeppel Glyn, Director of SPG played safe and bought shares in May at $50, but it is not late at all, the stock is now $90.